prikaz prve stranice dokumenta Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses
  Preuzmi
PDF 349.03 KB
Znanstveni rad - Prikaz slučaja
Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses
Journal of Neuroimmunology, 313 (2017); 89-91. https://doi.org/10.1016/j.jneuroim.2017.10.009
Rolla, Simona; De Mercanti, Stefania Federica; Bardina, Valentina; Horakova, Dana; Habek, Mario; Adamec, Ivan; Cocco, Eleonora; Annovazzi, Pietro; Vladić, Anton; Novelli, Francesco; Durelli, Luca; Clerico, Marinella

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Rolla, S., De Mercanti, S. F., Bardina, V., Horakova, D., Habek, M., Adamec, I. ... Clerico, M. (2017). Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses. Journal of Neuroimmunology, 313., 89-91. doi: 10.1016/j.jneuroim.2017.10.009

Rolla, Simona, et al. "Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses." Journal of Neuroimmunology, vol. 313, 2017, str. 89-91. https://doi.org/10.1016/j.jneuroim.2017.10.009

Rolla, Simona, Stefania Federica De Mercanti, Valentina Bardina, Dana Horakova, Mario Habek, Ivan Adamec, Eleonora Cocco, et al. "Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses." Journal of Neuroimmunology 313 (2017): 89-91. https://doi.org/10.1016/j.jneuroim.2017.10.009

Rolla, S., et al. (2017) 'Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses', Journal of Neuroimmunology, 313, str. 89-91. doi: 10.1016/j.jneuroim.2017.10.009

Rolla S, De Mercanti SF, Bardina V, Horakova D, Habek M, Adamec I, i sur.. Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses. Journal of Neuroimmunology [Internet]. 15.12.2017. [pristupljeno 29.12.2024.];313:89-91. doi: 10.1016/j.jneuroim.2017.10.009

S. Rolla, et al., "Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses", Journal of Neuroimmunology, vol. 313, str. 89-91, Prosinac 2017. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:194192. [Citirano: 29.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:194192
Podaci o radu
Naslov (engleski)Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses
AutorSimona Rolla
AutorStefania Federica De Mercanti
AutorValentina Bardina
AutorDana Horakova
AutorMario Habek
AutorIvan Adamec
AutorEleonora Cocco
AutorPietro Annovazzi
AutorAnton Vladić
AutorFrancesco Novelli
AutorLuca Durelli
AutorMarinella Clerico
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
Alemtuzumab, a highly effective treatment for relapsing remitting multiple sclerosis (RRMS), induces lymphopenia especially of CD4+ T cells. Here, we report the atypical CD4+ T population behaviour of two patients with persistent disease activity despite repeated alemtuzumab treatments. Whereas lymphocytes count decreased and fluctuated accordingly to alemtuzumab administration, their CD4+ cell percentage was not or just mildly affected and was slightly below the lowest normal limit already before alemtuzumab. These cases anticipate further studies aimed to investigate whether the evaluation of the CD4+ cell percentage could represent a helpful tool to address the individual clinical response to alemtuzumab.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Prikaz slučaja
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaJournal of Neuroimmunology
Brojčani podacivol. 313, str. 89-91
p-ISSN0165-5728
DOIhttps://doi.org/10.1016/j.jneuroim.2017.10.009
URN:NBNurn:nbn:hr:105:194192
Datum objave publikacije2017-12-15
URL dokumentahttps://doi.org/10.1016/j.jneuroim.2017.10.009
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 09:56:44